Purple Biotech Ltd.

Regulatory Filings • Apr 3, 2019

_________ false

����� ����� ��"�	2 379
KITOV PHARMA LTD
Corporation no: 520031238	10994
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C001 ( Public )		Reported via MAGNA:	03/04/2019
	www.isa.gov.il			www.tase.co.il				Reference:	2019-02-032635	Time of broadcast: 14:54 14:52:00

Complementary report for a report sent on date 26/03/2019 whose reference number was 2019-02-026968

Main details added/ completed:

This Amendment No. 1 (this �Amendment�) to our annual report on Form 20-F for the fiscal year ended December 31, 2018 (the �Form 20-F�), filed on March 26, 2019 (the �Original Filing Date�), is being filed solely to correct the hyperlinks on Exhibits 2.9 and 2.10, and to replace Exhibits 4.15, 4.16 and 4.17 with the attached Exhibits 4.15, 4.16 and 4.17 (the �Exhibits�) to reflect amendments to paragraph 4(a) of Instructions as to Exhibits of Form 20-F, governing redaction of confidential information in material contracts, which became effective as of April 2, 2019. Additionally, in connection with the filing of this Amendment, the Company is including certifications of the Company�s Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.1350) as no financial statements are being filed with this Amendment. Except for the revised Exhibits, this Amendment does not amend any other information set forth in the Form 20-F. This Amendment speaks as of the Original Filing Date, does not reflect any events that may have occurred subsequent to the Original Filing Date, and does not modify or update in any way any disclosures made in the Form 20-F.

---

Report of Periodic or Interim ReportRegulation 3 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

Please note that in the case of delayed publication of report, no changes will be allowed after the form is submitted.

	Delay the publication of a report	_________	_________

1. The delay of the report can be done up to 72 hours maximum from the date of filling out the form.2. Attention that in accordance with the provisions of the law, the reporting date must be simultaneous with the report in the foreign exchange.

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onForm 20-F/A

f20f2018a1_kitovpharmaltdAS-FILED_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 19/02/2019
Address: Menachem Begin St, Azrieli Towers Round Tower 132 , Tel Aviv 6701101   , Israel Tel: 03-9333121 , Fax: 03-5097196
E-mail address: info@kitovpharma.com   Company site: www.kitovpharma.com
Previous names of reporting entity: KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: BEN-TZVI ABRAHAM SHLOMO Position of Signatory in the reporting corporation: Chief Legal Officer & Secretary Name of Employer Company:
Address: Menachem Begin St, Azrieli Towers Round Tower 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: avraham@kitovpharma.com 1
Israel